This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Employment-based Reinforcement of Naltrexone Ingestion and Abstinence

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00149669
First received: September 6, 2005
Last updated: August 14, 2017
Last verified: August 2017
September 6, 2005
August 14, 2017
December 2005
December 2010   (Final data collection date for primary outcome measure)
Percentage of Urine Samples Positive for Naltrexone [ Time Frame: 6 months ]
The number of urine samples positive for naltrexone divided by the total number of urine samples times 100.
  • percentage of urine samples negative for naltrexone
  • percentage of urine samples negative for opiates
  • percentage of urine samples negative for cocaine
Complete list of historical versions of study NCT00149669 on ClinicalTrials.gov Archive Site
  • Percentage of Urine Samples Negative for Cocaine [ Time Frame: 6 months ]
    the number of urine samples that were negative for cocaine divided by the total number of urine samples) x 100
  • Percentage of Urine Samples Negative for Opiates [ Time Frame: 6 months ]
    The number of urine samples negative for opiates divided by the total number of urine samples times 100.
  • HIV risk behaviors
  • cost benefit analysis
  • percentage of urine/breath samples negative for other drugs of abuse
  • HIV Risk Behaviors [ Time Frame: 6 months ]
    Behaviors that place participants at risk for acquiring or transmitting HIV
  • Cost Benefit Analysis [ Time Frame: 6 months ]
    The costs and economic benefits of the intervention
  • Percentage of Urine/Breath Samples Negative for Other Drugs of Abuse [ Time Frame: 6 months ]
    The percentage of urine and breath samples that are negative for other drugs of abuse
  • Cocaine Positive Urine Samples [ Time Frame: 6 months ]
    The number of urine samples that were positive for cocaine
Not Provided
 
Employment-based Reinforcement of Naltrexone Ingestion and Abstinence
Employment-Based Addiction Pharmacotherapy
A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone ingestion and abstinence in unemployed opiate-dependent injection drug users. Participants will be offered an opioid detoxification and naltrexone induction. Participants who complete the naltrexone induction will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and prescribed naltrexone for 26 weeks. The groups will differ in the contingencies imposed to work and earn salary. Work Plus Naltrexone Contingency participants will be required to ingest naltrexone to work, and will receive a brief pay decrease for missing a dose. Work Plus Naltrexone Prescription participants will be prescribed naltrexone, but will not be required to ingest it to work. This study will provide a rigorous evaluation of a novel employment-based intervention, the Therapeutic Workplace, to promote naltrexone ingestion and drug abstinence in a population of injection drug users who are at considerable risk of spreading or contracting HIV infection. Hypotheses being tested in this study are: Naltrexone ingestion will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package. Opiate abstinence will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package.

General Therapeutic Workplace Procedures The study was conducted in a model therapeutic workplace in which employment-based reinforcement contingencies are arranged to promote therapeutic behavior change. All participants were invited to attend the workplace for four hours every weekday to work on training programs that were almost fully automated. Participants earned vouchers that were exchangeable for goods and services in the community. Earnings were based on attendance in the workplace and performance in the training programs. Overall, voucher earnings were arranged such that participants could earn a base pay of $8.00/hour for the hours worked in the workplace plus approximately $2.00/hour for their performance on the training programs, for a total potential wage of $10/hour. Detailed descriptions of the therapeutic workplace, the web-based training programs, the staffing requirements, and the cost of the intervention can be found elsewhere. Participants in the Prescription group were eligible to work and earn vouchers independent of naltrexone consumption and/or drug use, however Contingency participants were only permitted to work when naltrexone consumption was objectively confirmed.

Assessment Procedures Assessments were conducted at study intake and every 30 days throughout the study. Primary assessment measures included the Addiction Severity Index-Lite to evaluate changes in medical, employment, alcohol, drug, social, legal and psychological functioning; the opiate, cocaine, alcohol and nicotine sections of the Composite International Diagnostic Interview to evaluate psychiatric disorders; the Risk Assessment of Behavior to evaluate HIV-risk behaviors; and the Beck Depression Inventory-II and Symptom Checklist-90 to evaluate psychosocial functioning. Additional measures were collected.

Naltrexone is contraindicated for patients with hepatic damage or reductions in liver functioning, and is rated in the FDA pregnancy category C. Therefore, blood samples were taken at intake, and months 1, 2, 3, and 5 for liver function (aminotransferase) levels, and pregnancy tests were conducted monthly. Naltrexone was discontinued permanently for one Contingency and one Prescription participant, and temporarily for one Contingency and one Prescription participant due to abnormal aminotransferase levels. Naltrexone was discontinued for one Contingency participant due to pregnancy.

Urine samples were collected under same-sex staff observation upon arrival to the workplace every Monday, Wednesday, and Friday and at each 30-day assessment. Urine samples were analyzed immediately onsite for evidence of opiates (morphine, >300ng/ml), and cocaine (benzoylecgonine, >300ng/ml) using an Abbott AxSYM® fluorescent polarization immunoassay system. Samples collected at 30-day assessments were also analyzed for evidence of buprenorphine, methadone, amphetamine, benzodiazepines, and naltrexone. Urine samples were analyzed for naltrexone using an Enzyme Linked Immunosorbent Assay (ELISA) procedure; values <5ng/ml were considered negative for naltrexone (Friends Laboratory, MD). Participants were informed of their urinalysis results but there were no consequences for positive test results.

Participants were instructed to notify study staff of any adverse events they experienced as soon as possible after the occurrence of the event. Any staff member who was notified by a participant of a potential adverse event filed a formal report into an automated system, which immediately distributed the reports to study investigators and key staff. Ongoing or unresolved adverse events were also included in a weekly adverse event report that was distributed to study investigators and key staff. At all 30-day assessments study staff assessed new adverse events and attempted to resolve any ongoing or unresolved adverse events. Participants were referred to medical staff to receive treatments and concomitant medications as needed, and reports were filed with the Institutional Review Board (IRB) and funding agency in accordance with the relevant institutional requirements and guidelines.

Oral Naltrexone Treatment Participants were required to complete opiate detoxification before being invited to attend the therapeutic workplace for induction onto oral naltrexone (Depade®; Mallinckrodt Inc.). All opiate detoxification and naltrexone inductions were overseen by a physician and were guided solely by clinical considerations. All participants were notified of the potential for heightened risk of overdose in relation to naltrexone treatment and after extended periods of opiate abstinence. These notifications were issued by study staff during the study consent process, and at monthly assessments, and were issued by medical staff prior to initiating naltrexone treatment, and whenever a blood draw was conducted. Overdose risk reminders were read aloud and signed by the study participants. Finally, monthly lunch-time overdose prevention seminars were provided and free pizza was provided to encourage seminar attendance.

During the 4-week induction period, participants were required to ingest scheduled doses of oral naltrexone to gain access to the therapeutic workplace. Induction onto oral naltrexone was determined by clinical judgment; participants were generally inducted using a 3-day dose run-up schedule (e.g., 12.5 mg, 25 mg, and 50 mg) in order to reach the full maintenance dose of 100 mg (Monday and Wednesday) and 150 mg (Friday) for the four-week period. Only participants who completed the induction period were considered eligible for randomization; these participants were invited to attend the therapeutic workplace for 26 weeks, and were offered oral naltrexone at no cost for the duration of the study. Participants were also offered access to outpatient drug abuse counseling that was provided independent of the workplace throughout their participation in the study.

Randomization Prior to group assignment, participants were stratified to an experimental group in a 1:1 ratio according to whether they attended the workplace on >85% of days during the 4-week induction period, provided >1 opiate positive urine sample during the final 2 weeks of the induction period, and provided >75% cocaine-positive urine samples during the 4-week induction period. Eligible participants were assigned to one of two experimental groups (i.e., Prescription or Contingency) using an urn randomization method that ensured all levels of each stratification variable were evenly distributed across the groups. This research design originally proposed three experimental groups; therefore, four participants were randomized into a third experimental group that required participants to ingest naltrexone under staff observation and provide an opiate and cocaine-negative urine sample to maintain maximum pay in the workplace. Due to logistical difficulties encountered early in the study, it became clear that it would not be possible to randomize a sample size large enough to support a 3-group comparison within the planned study duration. A second power analysis was completed to determine the appropriate sample size for a 2-group comparison (described below) and the third experimental group was eliminated. Data from participants randomized into the third group have not been included in these analyses.

Experimental Groups All participants were invited to attend the therapeutic workplace for 26 weeks. Prescription group participants were provided a take-home supply of oral naltrexone every 30 days and were allowed to access the workplace independent of naltrexone ingestion. Contingency participants were required to ingest oral naltrexone under staff observation every Monday, Wednesday, and Friday to gain access to the workplace. Contingency participants who missed a naltrexone dose were not permitted to access the workplace until they were able to resume naltrexone. Additionally, missing a scheduled dose resulted in a base pay reset from $8 per hour to $1 per hour. After a reset a participant's base pay increased by $1 per hour to a maximum of $8 per hour for every day that a participant attended the workplace for at least 5 minutes.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Cocaine-Related Disorders
  • Heroin Dependence
  • Opioid-Related Disorders
  • Substance Abuse, Intravenous
Behavioral: employment-based reinforcement
Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
  • No Intervention: Work Plus Naltrexone Prescription
    Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
  • Experimental: Work Plus Naltrexone Contingency
    Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
    Intervention: Behavioral: employment-based reinforcement

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
December 2010
December 2010   (Final data collection date for primary outcome measure)

Volunteers were eligible to participate if they

  • were between the ages of 18 and 65 years,
  • were unemployed (i.e., reporting no work in the past 30 days and earning $200 in taxable income per month),
  • self-reported injection drug use and had visible track marks (assessed via visual inspection),
  • provided a urine sample that tested positive for both opiates and cocaine upon entry into detoxification,
  • met DSM-IV-TR criteria for opiate dependence,
  • were medically approved to be maintained on naltrexone by the study physician,
  • and lived within reasonable commuting distance to the research unit (i.e., in Baltimore City and the immediate surrounding area).

Volunteers were excluded if they

  • had active hallucinations, delusions, or a thought disorder;
  • were judged to be of imminent threat to harm self or others;
  • were currently incarcerated, in a halfway house, or under constant monitoring;
  • were pregnant or breastfeeding;
  • had serum aminotransferase levels over 3 times normal;
  • required opiates for other medical problems (and thus could not be maintained on naltrexone, which would block the effects on any opiate);
  • reported an interest in methadone treatment;
  • had active tuberculosis;
  • or had physical limitations that would prevent typing
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00149669
NA_00039284
R01DA019386 ( U.S. NIH Grant/Contract )
NA_00039284 ( Other Identifier: Johns Hopkins Medicine IRB )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: No
Johns Hopkins University
Johns Hopkins University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Kenneth Silverman, Ph.D. Johns Hopkins University
Johns Hopkins University
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP